KOPRAN The co. has set up a new API plant at Panoli, commercial production at this facility is expected to be started from Q3 FY25. In FY23, it completed upgradation and expansion of the multi-product plant at the Mahad facility for existing products and to manufacture new molecules.
An integrated Pharmaceutical Company, committed to supplying International
Quality Formulations and Active Pharmaceutical Ingredients (APIs) globally.
State-of-the-art manufacturing facilities and products with various accreditations
and approvals by major global regulatory authorities.
The formulations vertical is operated through Kopran Limited.
The API vertical is being operated under Kopran Research Laboratories Ltd.
(KRLL), a wholly owned subsidiary of Kopran Limited
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.